Ranolazine dihydrochloride
CAS: 95635-56-6
Ref. TM-T0207
| 1g | 203.00 € | ||
| 50mg | 52.00 € | ||
| 100mg | 68.00 € | ||
| 200mg | 94.00 € | ||
| 500mg | 154.00 € | ||
| 1mL*10mM (DMSO) | 69.00 € |
Estimated delivery in United States, on Wednesday 4 Dec 2024
Product Information
Name:
Ranolazine dihydrochloride
Synonyms:
- RS 43285
- Ranolazine 2HCl
- (+/-)-4-[2-Hydroxy-3-(O-Methoxyphenoxy)Propyl]-1-Piperazineaceto-2',6'-Xylidide Dihydrochloride
- (+/-)-N-(2,6-Dimethylphenyl)-4-[2-Hydroxy-3-(2-Methoxyphenoxy)Propyl]-1-Piperazineacetamide Dihydrochloride
- (±)-N-(2,6-dimethylphenyl)-4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]-1-piperazineacetamide
- (±)-Rs 43285-193
- 1-Piperazineacetamide, N-(2,6-dimethylphenyl)-4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]-, dihydrochloride
- 1-Piperazineacetamide, N-(2,6-dimethylphenyl)-4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]-, hydrochloride (1:2)
- N-(2,6-Dimethylphenyl)-2-[4-[2-Hydroxy-3-(2-Methoxyphenoxy)Propyl]Piperazin-1-Yl]Acetamide Dihydrochloride
- Ranolazine Di Hcl
- See more synonyms
- Ranolazine DiHCI
- Ranolazine Dihydrochloride
- Ranolazine and salt
- Ranolazine hydrochloride
- Ranolazine2Hcl
- Rs 43285
Description:
Ranolazine 2HCl, an antianginal, treats arrhythmia by inhibiting sodium current without changing blood pressure or heart rate.
Notice:
Our products are intended for lab use only. For any other use, please contact us.
Brand:
Targetmol
Long term storage:
Notes:
Chemical properties
Molecular weight:
500.46
Formula:
C24H35Cl2N3O4
Purity:
100% - 99.93%
Color/Form:
White Crystalline Powder
MDL:
Melting point:
Boiling point:
Flash point:
Density:
Concentration:
EINECS:
Merck:
HS code:
Technical inquiry about: TM-T0207 Ranolazine dihydrochloride
Please use instead the cart to request a quotation or an order
If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.
